Literature DB >> 20412535

Tissue donation and virus safety: more nucleic acid amplification testing is needed.

A Pruss1, G Caspari, D H Krüger, J Blümel, C M Nübling, L Gürtler, W H Gerlich.   

Abstract

In tissue and organ transplantation, it is of great importance to avoid the transmission of blood-borne viruses to the recipient. While serologic testing for anti-human immunodeficiency virus (HIV)-1 and -2, anti-hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), anti-hepatitis B core antigen (HBc), and Treponema pallidum infection is mandatory, there is until now in most countries no explicit demand for nucleic acid amplification testing (NAT) to detect HIV, hepatitis B virus (HBV), and HCV infection. After a review of reports in the literature on viral transmission events, tissue-specific issues, and manufacturing and inactivation procedures, we evaluated the significance of HIV, HCV, and HBV detection using NAT  in  donors of various types of tissues and compared our results with the experiences of blood banking organizations. There is a significant risk of HIV, HCV, and HBV transmission by musculoskeletal tissues because of their high blood content and the high donor-recipient ratio. If no effective virus inactivation procedure for musculoskeletal tissue is applied, donors should be screened using NAT  for  HIV, HCV, and HBV. Serologically screened cardiovascular tissue carries a very low risk of HIV, HCV, or HBV transmission. Nevertheless, because effective virus inactivation is impossible (retention of tissue morphology) and the donor-recipient ratio may be as high as 1:10, we concluded that NAT  should be performed for HIV, HCV, and HBV as an additional safety measure. Although cornea allografts carry the lowest risk of transmitting HIV, HCV, and HBV  owing to corneal physiology, morphology, and the epidemiology of corneal diseases, NAT  for  HCV should still be performed. If the NAT  screening of a donor for HIV, HCV, and HBV is negative, quarantine storage of the donor tissue seems dispensable. In view of numerous synergistic effects with transfusion medicine, it would be advantageous for tissue banks to cooperate with blood bank laboratories in performing virological tests.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20412535     DOI: 10.1111/j.1399-3062.2010.00505.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  16 in total

Review 1.  Adverse reactions and events related to musculoskeletal allografts: reviewed by the World Health Organisation Project NOTIFY.

Authors:  M Hinsenkamp; L Muylle; T Eastlund; D Fehily; L Noël; D M Strong
Journal:  Int Orthop       Date:  2011-11-03       Impact factor: 3.075

2.  Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples.

Authors:  Knut Gubbe; Yvonne Scharnagl; Steffi Grosch; Torsten Tonn; Michael Schmidt; Kai M Hourfar; Andreas Karl; Erhard Seifried; Ina Wilkemeyer; Ulrich Kalus
Journal:  Transfus Med Hemother       Date:  2012-11-13       Impact factor: 3.747

3.  HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days.

Authors:  Annemarie Berger; Sabine Salla; Oliver T Keppler; Holger F Rabenau
Journal:  Transfus Med Hemother       Date:  2016-11-04       Impact factor: 3.747

4.  Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.

Authors:  Thomas Meyer; Susanne Polywka; Birgit Wulff; Carolin Edler; Ann Sophie Schröder; Ina Wilkemeyer; Ulrich Kalus; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2012-11-19       Impact factor: 3.747

Review 5.  [Prevention of infections due to musculoskeletal allografts].

Authors:  A Pruß
Journal:  Unfallchirurg       Date:  2017-11       Impact factor: 1.000

Review 6.  [Bone banks : The state-of-the-art].

Authors:  A Pruß; U Kalus
Journal:  Orthopade       Date:  2018-01       Impact factor: 1.087

7.  Inactivation Effect of Standard and Fractionated Electron Beam Irradiation on Enveloped and Non-Enveloped Viruses in a Tendon Transplant Model.

Authors:  Tanja Schmidt; Arnd T Hoburg; Uwe Gohs; Wolfgang Schumann; Jung-Won Sim-Brandenburg; Andreas Nitsche; Sven Scheffler; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2012-01-20       Impact factor: 3.747

Review 8.  Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?

Authors:  Pilar Solves; Vicente Mirabet; Manuel Alvarez
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

10.  Comparison of Total Immunoglobulin G in Ante- and Postmortem Blood Samples from Tissue Donors.

Authors:  Gudrun Larscheid; Tino Schulz; Hermann Herbst; Tina Trögel; Sascha Eulert; Axel Pruß; Jan Schroeter
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.